NGM Biopharmaceuticals Inc
NGMDelisted Apr 5, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001426332
NGM Biopharmaceuticals Inc was delisted on Apr 5, 2024; its insiders filed their last Form 4 on Apr 8, 2024; 75 institutions reported holding it in 13F filings for Q1 2024, worth $55.1M in total; no superinvestor held it.
13F holders, Q2 2021
Institutional positions in NGM Biopharmaceuticals Inc as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 107
- −1 vs. Q1 2021
- Shares held
- 43.1M
- +52.5K (+0.1%) vs. Q1 2021
- Total value
- $849.7M
- −$401.2M (−32.1%) vs. Q1 2021
- New holders
- 18
- 46 more added
- Sold out
- 19
- 21 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NGM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 75 | $55.1M |
| Q4 2023 | 83 | $35.3M |
| Q3 2023 | 95 | $50.6M |
| Q2 2023 | 106 | $124.4M |
| Q1 2023 | 123 | $200.4M |
| Q4 2022 | 125 | $248.9M |
| Q3 2022 | 128 | $689.9M |
| Q2 2022 | 124 | $607.3M |
| Q1 2022 | 114 | $732.8M |
| Q4 2021 | 119 | $833.5M |
| Q3 2021 | 121 | $951.2M |
| Q2 2021 | 107 | $849.7M |
| Q1 2021 | 108 | $1.25B |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding NGM Biopharmaceuticals Inc; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 1,389,074 | $27.4M | 0.00% | −852,374−38.0% | Reduced |
| Euclidean Capital LLC | 1,493,349 | $29.4M | 9.56% | 00.0% | Unchanged |
| Greenspring Associates, LLC | 1,573,357 | $31.0M | 2.10% | 00.0% | Unchanged |
| BlackRock Inc. | 2,299,355 | $45.3M | 0.00% | −465,225−16.8% | Reduced |
| Redmile Group, LLC | 2,792,448 | $55.1M | 0.81% | +40,633+1.5% | Added |
| Rho Capital Partners Inc | 3,766,666 | $74.3M | 6.80% | 00.0% | Unchanged |
| The Column Group LLC | 15,396,116 | $303.6M | 42.97% | 00.0% | Unchanged |
| Farallon Capital Management, L.L.C. | 0 | $0 | 0.00% | −375,000−100.0% | Sold out |
| Rock Springs Capital Management LP | 0 | $0 | 0.00% | −364,800−100.0% | Sold out |
| Raymond James & Associates | 0 | $0 | 0.00% | −80,692−100.0% | Sold out |
| Marshall Wace North America L.P. | 0 | $0 | 0.00% | −55,953−100.0% | Sold out |
| California Public Employees Retirement System | 0 | $0 | 0.00% | −48,500−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −45,577−100.0% | Sold out |
| Aviva PLC | 0 | $0 | 0.00% | −42,095−100.0% | Sold out |
| Martingale Asset Management L P | 0 | $0 | 0.00% | −13,310−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −8,996−100.0% | Sold out |
| Cambridge Investment Research Advisors, Inc. | 0 | $0 | 0.00% | −8,306−100.0% | Sold out |
| Checchi Capital Advisers, LLC | 0 | $0 | 0.00% | −8,000−100.0% | Sold out |
| Beacon Investment Advisory Services, Inc. | 0 | $0 | 0.00% | −7,071−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −771−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −633−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −270−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −24−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −27−100.0% | Sold out |
| Meridian Wealth Partners, LLC | 0 | $0 | 0.00% | −26−100.0% | Sold out |